Nevertheless, the strong correlations between serum NfL and the disability scores during the full course of the disease may suggest that longitudinal monitoring of serum NfL could hold potential as an objective (intermediate) outcome measure to evaluate new treatments for GBS. The gene discussed is NEFL; the disease is Guillain-Barre syndrome.